
|Articles|December 9, 2014
T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL
Author(s)Stephan Grupp, MD, PhD
In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.
Advertisement
Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, discusses the long-term, follow-up data from a trial using CAR T-cell therapy in 39 children and young adults with relapsed, treatment-resistant acute lymphocytic leukemia.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – February 11, 2026
2
FDA Slams REGENXBIO's MPS II Gene Therapy RGX-121 With CRL
3
Guess the Therapy Answer February 11, 2026
4
ImmunoLogic, Episode 8: "Surgery Meets Immunotherapy: A One-Two Punch for Breast Cancer" With Julia C. Tchou, MD, PhD, FACS
5














